4 completed, 1 suspended, 1 terminated, 1 withdrawn. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Suspended 1, Terminated 1, Withdrawn 1 |
Follow Lung Disease: new trials by email Literature Review of Lung Disease trials Research Report on Lung Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Biological NTLA-3001 - Lung Disease, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Intellia Therapeutics | 2024-11-20 | 2025-01-17 | |
| Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders lipoaspiration, ADcSVF, Normal Saline IV - Lung Disease | Phase 1 / Phase 2 | Suspended | Healeon Medical Inc | 100 | 2016-10-01 | 2025-09-12 |
| Regional Lung Imaging Using Hyperpolarized Xenon Gas Hyperpolarized xenon - Lung Disease | Phase 1 | Completed | Oxford University Hospitals NHS Trust | 17 | 2012-04-01 | 2022-02-23 |
| To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart AZD3199, Moxifloxacin, Placebo comparator - Chronic Obstructive Pulmonary Disease, Lung Disease | Phase 1 | Completed | AstraZeneca | 40 | 2010-11-01 | 2011-02-16 |
| A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers PF-00610355, moxifloxacin, placebo - Pulmonary Disease, Lung Disease | Phase 1 | Completed | Pfizer | 48 | 2010-06-01 | 2011-01-13 |
| Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation nitric oxide for inhalation, Oxygen - Lung Disease, Hypoxemia | Phase 1 / Phase 2 | Terminated | Mallinckrodt | 7 | 2002-05-01 | 2016-10-19 |
| Effects of Endotoxin in Normal Human Volunteers Reference Endotoxin, Inhaled Nitric Oxide - Healthy, Lung Disease | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 198 | 1992-04-06 | 2018-07-05 |
Lung Diseases (7) · Emphysema (2) · Pulmonary Disease, Chronic Obstructive (2) · Acidosis, Respiratory (1) · Bronchiolitis (1) · Hypoxia (1) · Respiration Disorders (1) · Sepsis (1) · Shock, Septic (1) · alpha 1-Antitrypsin Deficiency (1)
Respiratory Tract Diseases (7) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Chronic Disease (2) · Disease Attributes (2) · Infections (2) · Lung Diseases, Obstructive (2) · Acid-Base Imbalance (1) · Acidosis (1) · Bronchial Diseases (1) · Bronchitis (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Emphysema (1) · Genetic Diseases, Inborn (1)
Moxifloxacin (2) · AZD-3199 (1) · Endothelium-Dependent Relaxing Factors (1) · Inhalation (1) · N-((4'-hydroxybiphenyl-3-yl)methyl)-2-(3-(2-((-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)phenyl)acetamide (1) · Nitric Oxide (1) · Oxygen (1)
AstraZeneca (1) · Healeon Medical Inc (1) · Intellia Therapeutics (1) · Mallinckrodt (1) · National Institutes of Health Clinical Center (CC) (1) · Oxford University Hospitals NHS Trust (1) · Pfizer (1)
United States (3) · United Kingdom (2) · Belgium (1) · Honduras (1) · New Zealand (1)
Anthony F Suffredini, M.D. (1) · Carin Jorup, MD (1) · Fergus V Gleeson (1) · Glenn C. Terry, MD (1) · Leonard Siew, MB CHB (1) · Robert W Alexander, MD (1) · Waldemar Carlo, MD (1)
PMID 16235359, PMID 16565429, PMID 16636091, PMID 16690673, PMID 17132052, PMID 17507545, PMID 18073405, PMID 19183804, PMID 21975749, PMID 22314182, PMID 22761482, PMID 22793939, PMID 22793945, PMID 23074435, PMID 23076942, PMID 23235687, PMID 23256721, PMID 23364286, PMID 2337756, PMID 23992090, PMID 24563632, PMID 24615270, PMID 25450456